Company: INTS
Filing Date: 2025-08-28
Form Type: PRE 14A
Source: 0001567264-25-000087
Chunk: 1

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-08-28
Form: PRE 14A
Chunk 1
---
Details regarding the Special Meeting, the business to be conducted at the Special Meeting, and information about the Company that you should consider when you vote your shares are described in the accompanying proxy statement.

We hope you will be able to attend the Special Meeting. Whether you plan to attend the Special Meeting or not, it is important that you cast your vote either in person or by proxy. You may vote over the internet as well as by telephone or by mail. When you have finished reading the proxy statement, you are urged to vote in accordance with the instructions set forth in the proxy statement. We encourage you to vote by proxy so that your shares will be represented and voted at the meeting, whether or not you can attend.

Thank you for your continued support of the Company.

Sincerely,

#### Lewis H. Bender

#### President, Chief Executive Officer and Chairman
<div align='center'>PRELIMINARY PROXY MATERIALS FILED PURSUANT TO RULE 14a-6(a)</div>

#### SUBJECT TO COMPLETION, DATED AUGUST 28, 2025

#### Intensity Therapeutics, Inc.

#### 1 Enterprise Drive, Suite 430

#### Shelton, CT 06484

### NOTICE OF SPECIAL MEETING OF STOCKHOLDERS

#### To Be Held on October 22, 2025
Dear Stockholder:

You are cordially invited to attend a special meeting of stockholders (the “Special Meeting”) of Intensity Therapeutics, Inc., a Delaware corporation. The meeting will be held on October 22, 2025, beginning at 10:30a.m. Eastern time via a live webcast at www.virtualshareholdermeeting.com/INTS2025SM. You will not be able to attend the Special Meeting in person. The Special Meeting will be held for the following purposes:

1. The approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our common stock by a ratio of not less than one-for-five and not more than one-for-thirty (the “Reverse Stock Split”), with the exact ratio to be set within this range by our board of directors in its sole discretion (without reducing the authorized number of shares of our common stock) and with our board of directors able to elect to abandon such proposed amendment and not effect the Reverse Stock Split authorized by our stockholders in its sole discretion (the “Amendment Proposal”); and

2. The approval of the adjournment